NO980251L - Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse - Google Patents

Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse

Info

Publication number
NO980251L
NO980251L NO980251A NO980251A NO980251L NO 980251 L NO980251 L NO 980251L NO 980251 A NO980251 A NO 980251A NO 980251 A NO980251 A NO 980251A NO 980251 L NO980251 L NO 980251L
Authority
NO
Norway
Prior art keywords
treatment
hyperactivity disorder
concentration failure
failure
concentration
Prior art date
Application number
NO980251A
Other languages
English (en)
Other versions
NO980251D0 (no
Inventor
John H Heiligenstein
Bennett Coleman Laguzza
Steven M Paul
Gary D Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9525909.9A external-priority patent/GB9525909D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO980251D0 publication Critical patent/NO980251D0/no
Publication of NO980251L publication Critical patent/NO980251L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En gruppe propanaminer, norpinfrinopptaksinhibitorer, blir benyttet for å behandle kon- sentrasjonssvikt/hyperaktivitetsforstyrrelse.
NO980251A 1995-07-24 1998-01-20 Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse NO980251L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US137395P 1995-07-24 1995-07-24
US634995P 1995-11-08 1995-11-08
GBGB9525909.9A GB9525909D0 (en) 1995-12-19 1995-12-19 Treatment of attention-defecit/hyperactivity disorder
PCT/US1996/012047 WO1997003665A1 (en) 1995-07-24 1996-07-18 Treatment of attention-deficit/hyperactivity disorder

Publications (2)

Publication Number Publication Date
NO980251D0 NO980251D0 (no) 1998-01-20
NO980251L true NO980251L (no) 1998-01-20

Family

ID=27268037

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980251A NO980251L (no) 1995-07-24 1998-01-20 Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse

Country Status (14)

Country Link
EP (1) EP0756869A3 (no)
JP (1) JPH11510143A (no)
KR (1) KR19990035817A (no)
CN (1) CN1195287A (no)
AU (1) AU709704B2 (no)
CA (1) CA2227410A1 (no)
CZ (1) CZ16798A3 (no)
EA (1) EA000856B1 (no)
IL (1) IL122984A0 (no)
MX (1) MX9800589A (no)
NO (1) NO980251L (no)
NZ (1) NZ313076A (no)
WO (1) WO1997003665A1 (no)
YU (1) YU43996A (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
JP2001517628A (ja) * 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
EP1069900B1 (en) * 1998-04-09 2005-08-10 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of neuropsychiatric disorders
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
DE60324685D1 (de) 2002-08-23 2008-12-24 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
CA2532349A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
CA2883641C (en) 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN114767672A (zh) 2015-03-06 2022-07-22 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
EP3270920B1 (en) * 2015-03-20 2020-06-17 Intra-Cellular Therapies, Inc. Organic compounds
JP2020029447A (ja) * 2018-06-25 2020-02-27 大原薬品工業株式会社 腸溶性高分子及び抗付着剤を含有する顆粒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
EP0591581B1 (en) * 1992-10-08 1995-08-09 Eli Lilly And Company N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
AU709704B2 (en) 1999-09-02
EP0756869A2 (en) 1997-02-05
JPH11510143A (ja) 1999-09-07
EA199800152A1 (ru) 1998-08-27
NZ313076A (en) 1999-11-29
MX9800589A (es) 1998-04-30
NO980251D0 (no) 1998-01-20
WO1997003665A1 (en) 1997-02-06
AU6506196A (en) 1997-02-18
CA2227410A1 (en) 1997-02-06
CZ16798A3 (cs) 1998-11-11
EP0756869A3 (en) 1999-06-16
IL122984A0 (en) 1998-08-16
YU43996A (sh) 1999-06-15
KR19990035817A (ko) 1999-05-25
EA000856B1 (ru) 2000-06-26
CN1195287A (zh) 1998-10-07

Similar Documents

Publication Publication Date Title
NO982055D0 (no) 2-alkylpyrrolidiner
NO991225D0 (no) Terapi for <alfa>-galaktosidase A mangel
NO954281L (no) Vannrensesystem
AU5624699A (en) Use of 5ht-6 antagonists
BG102644A (bg) Подобрени концентрирани инжекционни и инфузионниразтвори за интравазално прилагане
MX9606401A (es) Compuesto de indolinona para el tratamiento de enfermedades.
NO986100D0 (no) Androgene reseptormodulerende forbindelser og fremgangsmÕter
DK0768885T3 (da) Fremgangsmåde til inhibering af cancermetastase ved oral administration af oplöselig modificeret citruspectin
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
NL300180I2 (nl) Toepasen van toxmoxetine voor het behandelen van de concentratiestoornis/hyperactiviteit aandoening.
BR9808491A (pt) Compostos calcilìticos
EP0909561A3 (en) Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder
DE69432794D1 (de) Menschliche kalziumkanale und verwendungen davon
TR200102864T2 (tr) N”rolojik ya da n”ropsikiyatrik bozukluklarìn tedavisi i‡in y”ntem
ATE167670T1 (de) N-alkylthiopolyaminderivate als radioprotektive mittel
YU48698A (sh) Karboksamidni derivati pirolidina, piperidina i heksahidroazepina za lečenje oboljenja na bazi tromboze
NO980251D0 (no) Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse
EA199800867A1 (ru) Соединения тетрагидробетакарболина
DE59510131D1 (de) Imidazopyridin-azolidinone
YU13499A (sh) Primena 1-hidroksi-2-piridona za lečenje seboroitičnog dermatitisa
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
NO990450D0 (no) Behandling av sinnslidelser
TR200003203T2 (tr) Karboksaldehitin saflaştırılması
ATE231510T1 (de) Penamsulfone als beta-laktamase inhibitoren
NO972607L (no) Sekvestreringsmidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application